Drug Profile
Revaprazan
Alternative Names: Revanex; SB 641257; YH 1885; YH1885LLatest Information Update: 20 Apr 2021
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antiulcers; Isoquinolines; Small molecules
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Duodenal ulcer; Gastric ulcer; Gastritis
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 15 Apr 2021 Discontinued - Phase-II for Gastro-oesophageal reflux in South Korea (PO)
- 03 Feb 2016 No recent reports on development identified - Phase-II for Gastro-oesophageal reflux in South Korea (PO)
- 01 Apr 2014 Yuhan Corporation completes a phase II trial in non-erosive Gastro-oesophageal reflux in South Korea (NCT01750437)